Regulation of Prostaglandin Synthesis by Biological Response Modifiers and Effect on Natural Killer Cells and Bone Marrow

Part of the Prostaglandins, Leukotrienes, and Cancer book series (PLAC, volume 4)


Prostaglandins of the E-series (PGE) have been shown to have numerous effects on the cellular components of the immune system (for review see 1). PGE modulates the cytotoxicity of natural killer (NK) cells (2, 3) and also has been suggested to serve as a negative feedback regulator of macrophage-mediated cytotoxicity (4, 5). Immunoglobulin production by B cells is augmented by PGE (6), whereas blastogenesis of T cells after mitogen stimulation and cell-mediated immunity are inhibited by PGE (7, 8, 9). Growth and differentiation of the granulocyte-macrophage-committed stem cell (GM-CFU-C) in the bone marrow appears to be regulated by the antagonistic effects of colony-stimulating factor and PGE (10). Additionally, PGE production by tumor cells has been suggested to be a mechanism by which tumor cells can escape the host’s immune surveillance (11). The major source for PGE in the immune system has been shown to be monocytes and macrophages (Mø) (12). When stimulated with different agents, such as lipopolysaccharide (LPS) and zymosan, mononuclear phagocytes increase their PGE production and release high amounts of PGE (5, 13, 14). Several biological response modifiers (BRMs) have been reported to be Mø activators and some also augment NK cells (for review see 15). A few have also been shown to activate naive macrophages directly in vitro to express a tumoricidal response. Few studies have been conducted to assess whether BRMs, reported to be Mø activators, could alter PGE production.


Natural Killer Cell Bone Marrow Cell Natural Killer Activity Biological Response Modifier Divinyl Ether 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Goldyne ME, Stobo JD: Immunoregulatory role of prostaglandin and related lipids. CRC Crit Rev Immunol (2): 189, 1982.Google Scholar
  2. 2.
    Brunda MJ, Herberman RB, Holden HT: Inhibition of murine natural killer cell activty by prostaglandins. J Immunol (124): 2682, 1980.PubMedGoogle Scholar
  3. 3.
    Koren HS, Anderson SJ, Fischer DG, Copeland CS, Jensen PJ: Regulation of human natural killing. I. The role of monocytes, interferon and prostaglandins. J Immunol (127): 2007, 1981.Google Scholar
  4. 4.
    Schultz RM, Stoychkov JN, Pavlidis N, Chirigos MA, Olkowski ZL: Role of E-type prostaglandins in the regulation of interferon-treated macrophage cytotoxic activity. J Reticuloendothel Soc (26): 93, 1979.PubMedGoogle Scholar
  5. 5.
    Taffet SM, Russell SW: Macrophage-mediated tumor cell killing: Regulation of expression of cytolytic activity by prostaglandin E. J Immunol (126): 424, 1981.Google Scholar
  6. 6.
    Wieder KJ, Webb DR: The effect of prostaglandin metabolism on immunoglobulin and antibody production in naive and educated whole spleen cells. Prostaglandin Med (7): 79, 1981.CrossRefGoogle Scholar
  7. 7.
    Baker PE, Fahey JV, Munck A: Prostaglandin inhibition of T-cell proliferation is mediated at two levels. Cell Immunol (61): 52, 1981.PubMedCrossRefGoogle Scholar
  8. 8.
    Goodwin JS, Messner RP, Peake GT: Prostaglandin suppression of mitogen-stimulated lymphocytes in vitro. J Clin Invest (62): 753, 1978.PubMedCrossRefGoogle Scholar
  9. 9.
    Leung KH, Mihich E: Effects of prostaglandins on the development of cell-mediated immunity in culture and on the cytolytic activity of in vivo generated effector cells. Int J Immunopharmacol (4): 205, 1982.PubMedCrossRefGoogle Scholar
  10. 10.
    Pelus LM, Broxmeyer HE, Kurland JI, Moore MAS: Regulation of macrophage and granulocyte proliferation. J Exp Med (150): 277, 1979.PubMedCrossRefGoogle Scholar
  11. 11.
    Trevisani A, Ferretti E, Capuzzo A, Tomasi V: Elevated levels of prostaglandin E2 in Yoshida hepatoma and the inhibition of tumor growth by non-steroidal anti-inflammatory drugs. Br J Cancer (41): 341, 1980.PubMedCrossRefGoogle Scholar
  12. 12.
    Kurland JI, Bockman R: Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages. J Exp Med (147): 952, 1978.PubMedCrossRefGoogle Scholar
  13. 13.
    Bonney RJ, Wightman PD, Davies P, Sadowski SJ, Kuehl FA, Humes JL: Regulation of prostaglandin synthesis and of the selective release of lysosomal hydrolases by mouse peritoneal macrophages. Biochem J (176): 433, 1978.PubMedGoogle Scholar
  14. 14.
    Wahl LM, Rosenthal DL, Glode LM, Sandberg AL, Mergenhagen SE: Defective prostaglandin synthesis by C3H/HeJ mouse macrophages stimulated with endotoxin preparations. Infect Immun (23): 8, 1979.PubMedGoogle Scholar
  15. 15.
    Chirigos MA, Mitchell M, Mastrangelo MJ, Krim M: Mediation of Cellular Immuity in Cancer by Immune Modifiers. Raven Press, New York, 1981.Google Scholar
  16. 16.
    Stevenson HC, Katz P, Wright DG, Contreras TJ, Jemionek JF, Hartwig VM, Flor WJ, Fauci AS: Human blood monocytes: Characterization of negatively selected human monocytes and their suspension cell culture derivatives. Scand J Immunol (14): 1, 1981.CrossRefGoogle Scholar
  17. 17.
    Schlick E, Friedberg KD: Bone marrow cells of mice under the influence of low lead dose. Arch Toxicol (49): 227, 1982.PubMedCrossRefGoogle Scholar
  18. 18.
    Steel LK, Kaliner M: Prostaglandin-generating factor of anaphylaxis. J Biol Chem (256): 12692, 1981.PubMedGoogle Scholar
  19. 19.
    Steel LK, Platshon L, Kaliner M: Prostaglandin generation by human and guinea pig lung tissue. Comparison of parenchymal and airway responses. J Allergy Clin Immunol (64): 387, 1979.CrossRefGoogle Scholar
  20. 20.
    Pelus LM, Broxmeyer HE, DeSousa M, Moore MAS: Heterogeneity among resident murine peritoneal macrophages: Separation and functional characterization of monocytoid cells producing granulocyte-macrophage colony-stimulating (GM-CSF) and responding to regulation by lactoferrin. J Immunol (126): 1016, 1981.PubMedGoogle Scholar
  21. 21.
    Pelus LM, Broxmeyer HE, Kurland JI, Moore MAS: Regulation of macrophage and granulocyte proliferation. Specificities of prostaglandin E and lactoferrin. J Exp Med (150): 277, 1979.CrossRefGoogle Scholar
  22. 22.
    Herberman RB, Nunn ME, Lavrin DH: Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. Int J Cancer (16): 216, 1975.PubMedCrossRefGoogle Scholar
  23. 23.
    Chirigos MA, Mastrangelo MJ: Immunorestoration by chemicals. In: Mihich E (ed) Immunological approaches to cancer therapeutics. John Wiley & Sons, New York, 1982, pp 191–239.Google Scholar
  24. 24.
    Herberman RB, Brunda MJ, Cannon GB, Djeu JY, Nunn ME, Jett JR, Ortaldo JR, Reynolds C, Riccardi C, Santoni A. In: Hersh EM et al. (eds) Augmenting agents in cancer therapy. Raven Press, New York, 1981, pp 253–265.Google Scholar
  25. 25.
    Maluish AE, Ortaldo JR, Conlon JC, Sherwin SA, Leavitt R, Strong DM, Weirnik P, Oldham RK, Herberman RB: Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon. J Immunol (131): 503, 1983.PubMedGoogle Scholar
  26. 26.
    Bruley-Rosset M, Rappaport H: Natural killer cell activity and spontaneous lymphoma development. Effect of single and multiple injections of interferon in young and aged C57BL/6 mice. Int J Cancer (31): 381, 1983.PubMedCrossRefGoogle Scholar
  27. 27.
    Piccoli M, Saito T, Chirigos MA: Biomodal effects of MVE-2 on cytotoxic activity of natural killer cell and macrophage tumoricidal activities. Int J Immunopharmacol, 1984, in press.Google Scholar
  28. 28.
    Bartocci A, Papademetriou V, Chirigos MA: Enhanced macrophage and natural killer cell antitumor activity by various molecular weight maleic anydride divinyl ethers. J Immunopharmacol (2): 49, 1980.CrossRefGoogle Scholar
  29. 29.
    Yaron M, Yaron I, Wiletzki C, Zor U: Interrelationship between stimulation of prostaglandin E and hyaluronate production by poly (I) poly (C) and interferon in synovial fibroblast culture. Arthritis Rheum (21): 694, 1978.PubMedCrossRefGoogle Scholar
  30. 30.
    Lee SH, Epstein LB: Reversible inhibition by interferon of the maturation of human peripheral blood monocytes to macrophages. Cell Immunol (50): 177, 1980.PubMedCrossRefGoogle Scholar
  31. 31.
    Verma DS, Spitzer G, Zander AR, Gutterman JV, McCredie KB, Dicke KA, Johnston DA: Human leukocyte interferon preparation-mediated block of granulopoietic differentiation in vitro. Exp Hematol (9): 63, 1981.PubMedGoogle Scholar
  32. 32.
    Tracey DE, Adkinson, Jr. NF: Prostaglandin synthesis inhibitors potentiate the BCG-induced augmentation of natural killer cell activity. J Immunol (125): 136, 1980.PubMedGoogle Scholar
  33. 33.
    Schultz RM, Papamatheakis JD, Chirigos MA. In: Chirigos MA (ed) Immune modulation and control of neoplasia by adjuvant therapy. Raven Press, New York, 1978, pp 459.Google Scholar
  34. 34.
    Schultz RM, Pavlidis NA, Stylos WA, Chirigos MA: Regulation of macrophage tumoricidal function: A role for prostaglandins of the E series. Science (202): 320, 1978.Google Scholar
  35. 35.
    Schultz RM, Jackson WT. In: Chirigos MA, Mitchell M, Mastrangelo MJ, Krim M (eds) Mediation of cellular immunity in cancer by immune modifiers. Raven Press, New York, 1981, pp 89.Google Scholar
  36. 36.
    Shaw JO, Russell SW, Printz MP, Skidgel RA: Macrophage-mediated tumor cell killing: A lack of dependence on the cyclooxygenase pathway of prostaglandin synthesis. J Immunol (123): 50, 1979.PubMedGoogle Scholar
  37. 37.
    Kurland JI, Hadden JW, Moore MAS: Role of cyclic nucleotides in the proliferation of committed granulocyte-macrophage progenitor cells. Cancer Res (37): 4534, 1977.PubMedGoogle Scholar
  38. 38.
    Jaffee BM, Behrman HR, Parker CW: Radioimmunoassay measurement of prostaglandin E, A and F in human plasma. J Clin Invest (52): 398, 1973.CrossRefGoogle Scholar
  39. 39.
    Berenbaum MC, Cope WA, Bundick RV: Synergistic effect of cortisol and prostaglandin E2 on the PHA response. Clin Exp Immunol (26): 534, 1976.PubMedGoogle Scholar
  40. 40.
    Henney CS, Tracey DE, Durdik JM, Klimpel G: Natural killer cells: In vitro and in vivo. Am J Path (93): 459, 1978.PubMedGoogle Scholar
  41. 41.
    Roder JC, Klein M: Target-effector interactions in the natural killer cell system. II. Modulation by cyclic nucleotides. J Immunol (123): 2785, 1979.PubMedGoogle Scholar
  42. 42.
    Droller MJ, Schneider MV, Pearlmann P: A possible role for prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells. Cell Immunol (39): 165, 1978.PubMedCrossRefGoogle Scholar
  43. 43.
    Tracey DE, Davis JW, Taggart MT, Silberman SL: Modulation of natural killer cell activity by interferons and prostaglandins. Afr J Clin Exp Immunol (3): 19, 1982.Google Scholar
  44. 44.
    Unanue ER: The regulation of lymphocyte functions by the macrophage. Immunol Rev (40): 227, 1978.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

There are no affiliations available

Personalised recommendations